Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clemastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 8/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clemastine SCHEMBL4087919 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL23785539 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4058472 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL23785540 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4178 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL932384 | 0.99 | CHRM3 (0.98) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL8144354 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL13740733 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4088016 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4088154 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| US-8486923-B2 | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | TAKEDA GMBH (DE) | 2013-07-16 | — | — | US | claimed |
| EP-2295062-B1 | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | NYCOMED GMBH (DE) | 2012-08-29 | — | — | EP | claimed |
| JP-4746318-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| EP-2295062-A1 | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | Nycomed GmbH (DE) | 2011-03-16 | — | — | EP | claimed |
| EP-1545548-B1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | NYCOMED GMBH (DE) | 2010-06-30 | — | — | EP | claimed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | claimed |
| JP-2005539044-A | — | — | 2005-12-22 | — | — | JP | claimed |
| US-20050245493-A1 | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | claimed |
| EP-1545548-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA Pharma AG (DE) | 2005-06-29 | — | — | EP | claimed |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | claimed |
| EP-1482938-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2004019955-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| US-5648358-A | CAFFEINE AND PYRROLIDINE OR PIPERIDINE ETHER ANTIHISTAMINE | PROCTER & GAMBLE COMPANY, THE | 1997-07-15 | — | — | US | claimed |
| EP-0312108-B1 | CONTRAST MEDIUM FOR CANCEROUS GROWTH DIAGNOSIS | Bio-Photonics, Inc. (US) | 1992-07-01 | — | — | EP | claimed |
| EP-0433766-A1 | Compositions of antiallergics and antihistamines and methods for their use | ALCON LABORATORIES, INC. (US) | 1991-06-26 | — | — | EP | claimed |
| US-3933999-A | 1-METHYL-2-(2-(ALPHA-METHYL-P -CHLORODIPHENYLMETHOXY)ETHYL)PYRROLIDONE, RHINITIS, VASOCONSTRICTOR | SANDOZ LTD., (SANDOZ AG) (CH) | 1976-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | HRH1 11/4885CHRM3 70/4885ADRA1A 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.